Repeat Sentinel Lymph Node Biopsy in Ipsilateral Breast Tumor Recurrence
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
According to the standard treatment guidelines established until recently, in the case of ipsilateral breast tumor recurrence without systemic metastasis, salvage mastectomy or lumpectomy can be performed when either partial or whole breast radiation therapy is possible. On the other hand, there are currently no standard treatment guidelines for axillary treatment, and the evidence for this is limited. Axillary lymph node metastasis was reported to occur in about 26% of breast cancer patients who had negative sentinel lymph nodes from previous surgery for primary breast cancer and only local recurrence occurred. It is still important in the decision of treatment or adjuvant radiation therapy. However, it is known that most of the patients with ipsilateral breast recurrence do not have axillary lymph node metastasis. Therefore, performing axillary axillary surgery in all of these patients does not help the patient's survival in many cases, but rather can lead to complications such as lymphedema and seroma and postoperative wound infection. A question about the implementation of axillary lymph node resection has been raised and for this reason, it is necessary to study whether surveillance lymph node biopsy is still effective in patients with recurrence in the ipsilateral breast. Most of the studies on ipsilateral breast tumor recurrence without systemic metastasis reported to date are case reports or small retrospective studies. In addition, the combined meta-analysis also has limitations in that the study design is not uniform, and there are many cases in which primary breast cancer surgery performed total mastectomy or axillary lymph node dissection. This study is a multicenter prospective study designed to validate the clinical effectiveness of repeat-SLNB conducted in patients with ipsilateral breast tumor recurrence among patients who previously underwent breast conservation and sentinel lymph node biopsy for unilateral primary breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 19 lat
- •Pacjenci planowani do operacji z powodu nawrotu raka piersi po tej samej stronie (potwierdzone badaniem mikroskopowym)
- •Pacjenci, którzy mieli poprzednio zachowawczą operację piersi i biopsję węzłów chłonnych
- •Pacjenci bez klinicznych oznak choroby w węzłach chłonnych pachowy
- •Pacjenci, którzy rozumieją badanie i zgadzają się dobrowolnie uczestniczyć
✗ Disqualifies
- •Nawrót raka w innych miejscach (węzły chłonne, mosteczek)
- •Pacjenci, którzy nie mogą przejść biopsji węzła wartownika
- •Pacjenci, którzy mieli całkowitą mastektomię lub usunięcie węzłów chłonnych
- •Nawrót raka w ciągu roku od pierwszej operacji
- •Pacjenci z potwierdzonym przerzutem do węzłów chłonnych pachowych
- •Pacjenci z przerzutami w organach wewnętrznych
- •Pacjenci w ciąży lub karmiące piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 19 Years
- Last updated (source)
- October 11, 2023
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Gangnam Severance Hospital, Yonsei University College of Medicine
Seoul, South Korea
Trial contact
Soong June Bae, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.